Serviço de Endocrinologia, Diabetes e Metabolismo do Centro Hospitalar Universitário de São João, Porto, Portugal.
Departamento de Cirurgia e Fisiologia, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
Front Endocrinol (Lausanne). 2021 Aug 12;12:714173. doi: 10.3389/fendo.2021.714173. eCollection 2021.
Obesity is a multifactorial disease, which is strongly associated to other metabolic disorders. Bariatric surgery is the most effective treatment of morbid obesity. The role of beta cell function in weight loss after bariatric surgery is uncertain.
To evaluate the association between beta cell function and percentage of total body weight loss (TBWL%) 1, 2, 3, and 4 years after bariatric surgery in patients with morbid obesity.
Retrospective longitudinal study in patients with morbid obesity followed in our center between January 2010 and July 2018. Patients were excluded if they had diabetes at baseline or missing data on the needed parameters. We evaluated baseline Homeostatic Model Assessment of IR, Homeostatic Model Assessment of β-cell function (HOMA-beta), Quantitative Insulin Sensitivity Check Index, and Matsuda and DeFronzo index, and TBWL% at years 1 to 4. Linear regression models were used to evaluate the association of indexes of insulin resistance with TBWL% (unadjusted and adjusted for age, sex, BMI, and type of surgery).
There were 1,561 patients included in this analysis. HOMA-beta was negatively associated with TBWL% at second, third, and fourth years post-surgery (β = -1.04 [-1.82 to -0.26], p<0.01; β = -1.16 [-2.13 to -0.19], p=0.02; β = -1.29 [-2.64 to 0.06], p=0.061, respectively). This was not observed in the first year post-surgery nor for the other indexes. Glycemia at baseline was positively associated to EWL% at second and third years post-surgery.
β-cell function at baseline seems to be associated to long-term weight loss, explicitly after the first year post bariatric surgery. This might be a helpful predictor of weight loss in clinical practice.
肥胖是一种多因素疾病,与其他代谢紊乱密切相关。减重手术是治疗病态肥胖最有效的方法。β细胞功能在减重手术后体重减轻中的作用尚不确定。
评估病态肥胖患者减重手术后 1、2、3 和 4 年时β细胞功能与体重减轻百分比(TBWL%)之间的相关性。
对 2010 年 1 月至 2018 年 7 月在本中心随访的病态肥胖患者进行回顾性纵向研究。如果患者在基线时患有糖尿病或需要的参数缺失,则将其排除在外。我们评估了基线时的稳态模型评估胰岛素抵抗(HOMA-IR)、稳态模型评估β细胞功能(HOMA-β)、定量胰岛素敏感性检查指数和 Matsuda 和 DeFronzo 指数,以及术后 1 至 4 年的 TBWL%。线性回归模型用于评估胰岛素抵抗指数与 TBWL%之间的相关性(未调整和调整年龄、性别、BMI 和手术类型)。
共纳入 1561 例患者。HOMA-β 与术后第 2、3 和 4 年的 TBWL%呈负相关(β=-1.04[-1.82 至-0.26],p<0.01;β=-1.16[-2.13 至-0.19],p=0.02;β=-1.29[-2.64 至 0.06],p=0.061)。这在术后第 1 年或其他指数中均未观察到。基线时的血糖与术后第 2 和第 3 年的 EWL%呈正相关。
基线时的β细胞功能似乎与长期体重减轻相关,尤其是在减重手术后的第 1 年。这可能是临床实践中体重减轻的一个有用预测指标。